See more : Old National Bancorp (ONB) Income Statement Analysis – Financial Results
Complete financial analysis of Ulisse Biomed S.p.A. (UBM.MI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ulisse Biomed S.p.A., a leading company in the Biotechnology industry within the Healthcare sector.
- Kalyani Commercials Limited (KALYANI.NS) Income Statement Analysis – Financial Results
- Züblin Immobilien Holding AG (0REW.L) Income Statement Analysis – Financial Results
- Yamato Holdings Co., Ltd. (YATRY) Income Statement Analysis – Financial Results
- Metallurgical Corporation of China Ltd. (MLLUY) Income Statement Analysis – Financial Results
- SKSHU Paint Co.,Ltd. (603737.SS) Income Statement Analysis – Financial Results
Ulisse Biomed S.p.A. (UBM.MI)
About Ulisse Biomed S.p.A.
Ulisse Biomed S.p.A., a healthcare biotech company, provides diagnostic platforms and products. The company through its Sagitta platform offers various tests, such as Ladymed/HPV Selfy for the detection of human papillomavirus (HPV); CoronaMelt, a diagnostic test for Sars- CoV-2; CoronaMelt Var, a diagnostic assay for the detection and genotyping of Sars-CoV-2 variants; and UlisseFaster, a reagent for the pre-treatment of biological samples. It also provides various tests and reagents for sexually transmitted diseases and HPV for oropharyngeal cancer. In addition, the company's platforms also comprise NanoHybrid, a DNA/PNA based multi-modal biomolecule platform to detect specific antibodies and protein analytes directly from serum or whole blood; and Aptavir platform to develop and produce synthetic nucleic acid molecules to limit the infectivity of pathogens. Ulisse Biomed S.p.A. was founded in 2015 and is based in Udine, Italy.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
---|---|---|---|---|---|---|
Revenue | 66.21K | 138.44K | 276.63K | 429.00K | 11.00K | 76.00 |
Cost of Revenue | 1.62M | 1.68M | 934.38K | 229.00K | 711.00K | 45.98K |
Gross Profit | -1.55M | -1.54M | -657.75K | 200.00K | -700.00K | -45.91K |
Gross Profit Ratio | -2,339.68% | -1,115.59% | -237.77% | 46.62% | -6,363.64% | -60,402.63% |
Research & Development | 1.30M | 504.32K | 243.10K | 273.97K | 0.00 | 0.00 |
General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 609.71K | -348.24K | -162.50K | -196.97K | 189.66K | 1.42M |
Other Expenses | 0.00 | 0.00 | 0.00 | 80.00K | 417.00K | -401.16K |
Operating Expenses | 1.91M | 156.08K | 80.60K | 80.00K | 417.00K | 1.82M |
Cost & Expenses | 3.53M | 1.84M | 1.01M | 309.00K | 1.13M | 1.86M |
Interest Income | 191.00 | 48.00 | 0.00 | 0.00 | 0.00 | 26.00 |
Interest Expense | 139.00 | 164.00 | 206.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 2.65M | 319.64K | 247.72K | 50.86K | 55.63K | 45.98K |
EBITDA | -2.14M | -987.95K | -355.67K | 275.07K | -1.04M | -1.60M |
EBITDA Ratio | -3,235.81% | -997.44% | -177.36% | 39.86% | -9,645.45% | -2,390,078.95% |
Operating Income | -3.46M | -1.70M | -738.35K | 120.00K | -1.12M | -1.86M |
Operating Income Ratio | -5,224.58% | -1,228.33% | -266.91% | 27.97% | -10,145.45% | -2,450,578.95% |
Total Other Income/Expenses | -1.34M | 392.73K | 134.75K | 104.00K | 211.43K | -71.05K |
Income Before Tax | -4.80M | -1.31M | -603.60K | 224.00K | -1.10M | -1.93M |
Income Before Tax Ratio | -7,245.12% | -944.65% | -218.20% | 52.21% | -9,981.82% | -2,544,056.58% |
Income Tax Expense | 0.00 | 1.00 | 0.00 | 2.00K | -18.00K | -2.00 |
Net Income | -4.80M | -1.31M | -603.60K | 222.00K | -1.08M | -1.93M |
Net Income Ratio | -7,245.12% | -944.65% | -218.20% | 51.75% | -9,818.18% | -2,544,056.58% |
EPS | -0.22 | -0.16 | -0.07 | 0.03 | -0.15 | -0.27 |
EPS Diluted | -0.22 | -0.16 | -0.07 | 0.03 | -0.15 | -0.27 |
Weighted Avg Shares Out | 21.57M | 8.06M | 8.06M | 7.25M | 7.25M | 7.25M |
Weighted Avg Shares Out (Dil) | 21.57M | 8.06M | 8.06M | 7.25M | 7.25M | 7.25M |
Source: https://incomestatements.info
Category: Stock Reports